Illumina (NASDAQ: ILMN) and IRIDEX Corporation (NASDAQ:IRIX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Institutional & Insider Ownership

93.3% of Illumina shares are owned by institutional investors. Comparatively, 47.5% of IRIDEX Corporation shares are owned by institutional investors. 1.6% of Illumina shares are owned by insiders. Comparatively, 5.0% of IRIDEX Corporation shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


This table compares Illumina and IRIDEX Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Illumina 30.27% 19.69% 10.81%
IRIDEX Corporation -37.62% -16.87% -13.86%

Valuation & Earnings

This table compares Illumina and IRIDEX Corporation’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Illumina $2.49 billion 12.51 $666.78 million $5.10 41.85
IRIDEX Corporation $42.80 million 2.51 -$5.81 million ($1.51) -6.15

Illumina has higher revenue and earnings than IRIDEX Corporation. IRIDEX Corporation is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings for Illumina and IRIDEX Corporation, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Illumina 2 8 9 0 2.37
IRIDEX Corporation 0 0 1 0 3.00

Illumina currently has a consensus target price of $179.15, suggesting a potential downside of 16.06%. IRIDEX Corporation has a consensus target price of $20.00, suggesting a potential upside of 115.29%. Given IRIDEX Corporation’s stronger consensus rating and higher probable upside, analysts clearly believe IRIDEX Corporation is more favorable than Illumina.

Risk & Volatility

Illumina has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, IRIDEX Corporation has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.


Illumina beats IRIDEX Corporation on 9 of the 13 factors compared between the two stocks.

Illumina Company Profile

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company’s portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.

IRIDEX Corporation Company Profile

IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company’s ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with's FREE daily email newsletter.